[{"orgOrder":0,"company":"Mymetics","sponsor":"PCI Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mymetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mymetics \/ PCI Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Mymetics \/ PCI Biotech"}]

Find Clinical Drug Pipeline Developments & Deals by Mymetics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide
                          Not Confirmed
                          Boulder Peptide
                          Not Confirmed

                          Details : The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 31, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : PCI Biotech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank